Lawyers for the government gave the first substantive signal that the Trump administration will continue to defend Medicare ...
Has drug giant Roche finally cracked DNA sequencing? The company has claimed it can decode the genome in as little as four ...
Mother took Evrysdi for SMA before birth; baby later received Zolgensma. Dr. Richard Finkel at St. Jude led study showing no ...
UnitedHealthcare offers voluntary buyouts to 30,000 employees due to low attrition and digital shift, COO Michael Baker tells ...
Charles River Labs beats Q4 estimates, Theratechnologies resumes Egrifta SV distribution, FDA greenlights BCG alternative, ...
The Trump administration's respective nominees for CMS administrator and NIH director, Mehmet Oz and Jay Bhattacharya, ...
The European Union’s proposed ban of so-called “forever chemicals” is expected to become law this year, and investors are ...
BridgeBio revealed Thursday that prescriptions for its recently approved rare heart disease drug Attruby substantially beat ...
Eli Lilly, Bristol Myers Squibb, Sanofi and Novartis are seeking to block a major hospital trade group from intervening in court cases over their proposed 340B drug rebate models.
A meeting of CDC vaccine advisors has been postponed, according to a senior HHS official. “The ACIP meeting will be postponed to accommodate public comment … ...
Illumina to cut 96 San Diego jobs by April 14; Incyte partners with Genesis on AI for $30M upfront; 2048 Ventures plans $75M fund; Atai Life Sciences raises $63.2M ...
AstraZeneca is furthering its presence in China by gaining complete control of FibroGen's subsidiary in the country for about $160 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback